Stock Updates

How has Alexion Pharmaceuticals, Inc.:(NASDAQ:ALXN) performed recently?

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) is a large market cap stock with a market cap of 30350.85. It is in the Biotechnology industry and sector Healthcare, with a current P/E of 186.09, a forward P/E of 21.52 and EPS of 0.72. At a stock price of 137.22 (2.70%) it has a dividend yield of *TBA.

EPS growth for the last five years have been 5.10%, more recently this last year it has grown by -79.50%. The next year growth is going to be about 25.76% and more long-term 18.20% after five years. EPS growth quarter over quarter is -32.50%. Sales growth for the past five years have been 36.90% and sales growth quarter over quarter is 18.40%.

For performance, Alexion Pharmaceuticals, Inc. the past week has seen a gain of 5.50%. For the last month performance for Alexion Pharmaceuticals, Inc. is 12.67%. While the last quarter is -7.45% and half year, -2.73%. Finally for the year, performance is -31.74%.

The 52-week high for Alexion Pharmaceuticals, Inc., is at -31.72%, and for the 52-week low it comes to a value of 24.11%. The 20-day simple moving average is 4.95% and -9.19% for the 200-day simple moving average.

Volatility for the week is at 3.81%, and for the month it is 2.67%. Alexion Pharmaceuticals, Inc., has a target price of 174.65.

In terms of debt, long term debt/equity is *TBA, and for total debt/equity Alexion Pharmaceuticals, Inc. has *TBA. The gross margin is 91.80%, while operating margin is 24.90%, the profit margin is *TBA. The current ratio is *TBA and the quick ratio is *TBA.

Insider ownership is at 0.60%, with instituitional ownership at 98.70%. Alexion Pharmaceuticals, Inc. has a payout ratio of 0.00%. With the total shares outstanding coming to 227.16. The shares float is 223.19, with the float short at 2.85%, with short ratio coming to 3.2.

In terms of returns, the return on assets see Alexion Pharmaceuticals, Inc., get *TBA, with its returns on investment at 1.60%. Return on equity is *TBA. So will the investors see the target price of 174.65, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Tony Dabbs

Leave a Comment